JUL 31, 2018 08:25 PM PDT

Pill Approved For Endometriosis Treatment

WRITTEN BY: Nouran Amin

A first drug, by the name of Elagolix, to treat for endometriosis-related pain, has recently become approved by the US Food and Drug Administration. Endometriosis is caused by uterine tissue moving to another part of the body, usually around the pelvis. The pain, which affects one in ten young women, can cause severe pelvic discomfort during menstruation, sexual intercourse, or all the time. Currently, endometriosis-related pain is managed by common painkillers, contraceptives that work to lessen or block menstruation, or through injectable hormonal treatments. In many cases, women suffering from endometriosis do not benefit from these treatments because they either don’t work, produce unpleasant side-effects such as weight gain or moodiness, or administered for only short periods of time due to the effects of the treatment on bone density.

Fortunately, Elagolix may be taken for longer, but it does come with several side-effects. During a placebo-controlled clinical trial study that examined almost 900 women with moderate to severe endometriosis pain, Elagolix was seen to reduce menstrual pain in over 40 percent of affected women and non-menstrual pelvic pain in over 50 percent when taken orally as a once-daily pill. Elagolix was also seen to reduce average pain ratings during sexual intercourse. The science of Elagolix works by reducing estrogen, the hormone that drives endometriosis. It is believed that because Elagolix slightly reduces the estrogen levels, the drug can be taken for up to two years. On the other hand, injectable hormone treatments, which effectively lower estrogen more powerfully, can only be administered for 6 months because it causes bone loss.

The side-effects that come with taking Elagolix include hot flushes and headaches in about 20 percent of the patient’s examined in the clinical trial with nausea occurring in about 10 percent. “Despite these side-effects, any extra options for treating endometriosis are welcome,” says Elizabeth Farrell, a gynecologist at Jean Hailes, an Australian women’s health organization. Farrell believes that despite the effectiveness of Elagolix, it is unlikely that it will become a first-line treatment for patients. “The oral contraceptive pill or an IUD would probably still be the first thing you tried,” she says.

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 19, 2019
Drug Discovery & Development
NOV 19, 2019
Compound in Daffodils Can Help Fight Cancer
Preventing the growth of tumors presents a challenge for scientists in finding a cure to cancer. Now however, researchers from the University Libre de Brux...
NOV 19, 2019
Cancer
NOV 19, 2019
An alternative for immunotherapy-resistant cancer patients
A twist to traditional immunotherapies could help cancer patients’ immune systems better detect cancer cells, making this new system capable of targe...
NOV 19, 2019
Immunology
NOV 19, 2019
Treating Celiac Disease May Be Possible
Delivering gluten to the body in a friendly, harmless package may be the way for people with celiac disease to finally have a sandwich again. A new clinica...
NOV 19, 2019
Drug Discovery & Development
NOV 19, 2019
Treating Gulf-War Illness with Anti-Viral Drugs
Researchers at the University of South Carolina's Arnold School of Public Health have reported that repurposing existing FDA-approved antiviral drugs o...
NOV 19, 2019
Drug Discovery & Development
NOV 19, 2019
Advancing Nanocontainers for Drug Delivery
Nanocontainers work by delivering drugs to a localized region in the body, many chemotherapeutics work in that matter. The high specificity of this drug de...
NOV 19, 2019
Genetics & Genomics
NOV 19, 2019
Can CRISPR Replace Antibiotics?
Antibiotic-resistant infections claim around 700,000 lives per year, with estimates saying that this number could swell to 10 million by 2050 (Jacobs: 2019...
Loading Comments...